Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

A Reappraisal of Linezolid Dosing in Renal Impairment to Improve Safety.

Crass RL, Cojutti PG, Pai MP, Pea F.

Antimicrob Agents Chemother. 2019 May 20. pii: AAC.00605-19. doi: 10.1128/AAC.00605-19. [Epub ahead of print]

PMID:
31109977
2.

Repurposing azithromycin for neonatal neuroprotection.

Barks JDE, Liu Y, Wang L, Pai MP, Silverstein FS.

Pediatr Res. 2019 May 17. doi: 10.1038/s41390-019-0408-6. [Epub ahead of print]

PMID:
31100754
3.

Optimizing Estimated Glomerular Filtration Rate to Support Adult to Pediatric Pharmacokinetic Bridging Studies in Patients with Cystic Fibrosis.

Crass RL, Pai MP.

Clin Pharmacokinet. 2019 Apr 10. doi: 10.1007/s40262-019-00761-5. [Epub ahead of print]

PMID:
30972695
4.

Insights Into the Evolution of Staphylococcus aureus Daptomycin Resistance From an in vitro Bioreactor Model.

Lasek-Nesselquist E, Lu J, Schneider R, Ma Z, Russo V, Mishra S, Pai MP, Pata JD, McDonough KA, Malik M.

Front Microbiol. 2019 Feb 28;10:345. doi: 10.3389/fmicb.2019.00345. eCollection 2019.

5.

Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors.

Crass RL, Pai MP.

Pharmacotherapy. 2019 Feb;39(2):182-195. doi: 10.1002/phar.2210. Epub 2019 Jan 20. Review.

PMID:
30589457
6.

Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.

Bland CM, Pai MP, Lodise TP.

Pharmacotherapy. 2018 Dec;38(12):1229-1238. doi: 10.1002/phar.2193.

PMID:
30403305
7.

Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?

Crass RL, Pai MP, Lodise TP Jr.

J Antimicrob Chemother. 2019 Jan 1;74(1):126-129. doi: 10.1093/jac/dky388.

PMID:
30252050
8.

Renal Dosing of Antibiotics: Are We Jumping the Gun?

Crass RL, Rodvold KA, Mueller BA, Pai MP.

Clin Infect Dis. 2019 Apr 24;68(9):1596-1602. doi: 10.1093/cid/ciy790.

PMID:
30219824
9.

Dosing vancomycin in the super obese: less is more.

Crass RL, Dunn R, Hong J, Krop LC, Pai MP.

J Antimicrob Chemother. 2018 Nov 1;73(11):3081-3086. doi: 10.1093/jac/dky310.

PMID:
30203073
10.

Estimating Renal Function in Drug Development: Time to Take the Fork in the Road.

Crass RL, Pai MP.

J Clin Pharmacol. 2019 Feb;59(2):159-167. doi: 10.1002/jcph.1314. Epub 2018 Sep 5. Review.

PMID:
30184267
11.

Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.

Li F, Zhang H, He M, Liao J, Chen N, Li Y, Zhou S, Palmisano M, Yu A, Pai MP, Yuan H, Sun D.

Mol Pharm. 2018 Oct 1;15(10):4505-4516. doi: 10.1021/acs.molpharmaceut.8b00527. Epub 2018 Sep 21.

PMID:
30180593
12.

Validation of Heel Stick Microsampling To Optimize Micafungin Doses in Neonates and Young Infants.

Auriti C, Goffredo BM, Ronchetti MP, Piersigilli F, Cairoli S, Bersani I, Dotta A, Pai MP.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01199-18. doi: 10.1128/AAC.01199-18. Print 2018 Oct.

13.

A Fixed versus Weight-Based Dosing Strategy of Daptomycin May Improve Safety in Obese Adults.

Butterfield-Cowper JM, Lodise TP Jr, Pai MP.

Pharmacotherapy. 2018 Sep;38(9):981-985. doi: 10.1002/phar.2157. Epub 2018 Jul 12.

PMID:
29906315
14.

Characterization of genetic changes associated with daptomycin nonsusceptibility in Staphylococcus aureus.

Ma Z, Lasek-Nesselquist E, Lu J, Schneider R, Shah R, Oliva G, Pata J, McDonough K, Pai MP, Rose WE, Sakoulas G, Malik M.

PLoS One. 2018 Jun 7;13(6):e0198366. doi: 10.1371/journal.pone.0198366. eCollection 2018.

15.

In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations.

Pai AB, Pai MP, Meyer DE, Bales BC, Cotero VE, Zheng N, Jiang W.

Regul Toxicol Pharmacol. 2018 Aug;97:17-23. doi: 10.1016/j.yrtph.2018.05.014. Epub 2018 May 29.

PMID:
29857115
16.

Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.

Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Lavoie Smith EM, Henry NL.

Clin Cancer Res. 2018 Aug 1;24(15):3602-3610. doi: 10.1158/1078-0432.CCR-18-0656. Epub 2018 Apr 27.

PMID:
29703818
17.

Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size.

Crass RL, Ross BE, Derstine BA, Lichty M, Sullivan JA, Su GL, Wang SC, Pai MP.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00441-18. doi: 10.1128/AAC.00441-18. Print 2018 Jun.

18.

Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose.

Eschenauer GA, Carver PL, Patel TS, Lin SW, Klinker KP, Pai MP, Lam SW.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02566-17. doi: 10.1128/AAC.02566-17. Print 2018 Jun.

19.

Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.

Bunnell KL, Pai MP, Sikka M, Bleasdale SC, Wenzler E, Danziger LH, Rodvold KA.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02475-17. doi: 10.1128/AAC.02475-17. Print 2018 Apr.

20.

Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients.

Miglis C, Rhodes NJ, Avedissian SN, Kubin CJ, Yin MT, Nelson BC, Pai MP, Scheetz MH.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01475-17. doi: 10.1128/AAC.01475-17. Print 2018 Mar.

21.

Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.

Natesan S, Pai MP, Lodise TP.

J Antimicrob Chemother. 2017 Oct 1;72(10):2813-2816. doi: 10.1093/jac/dkx221.

PMID:
29091209
22.

Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.

Cojutti P, Pai MP, Pea F.

Clin Pharmacokinet. 2018 Aug;57(8):989-1000. doi: 10.1007/s40262-017-0606-5.

PMID:
29080937
23.

Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.

Conner TM, Nikolian VC, Georgoff PE, Pai MP, Alam HB, Sun D, Reed RC, Zhang T.

Eur J Pharm Sci. 2018 Jan 1;111:465-481. doi: 10.1016/j.ejps.2017.10.009. Epub 2017 Oct 10.

PMID:
29030176
24.

In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions.

Koenigsknecht MJ, Baker JR, Wen B, Frances A, Zhang H, Yu A, Zhao T, Tsume Y, Pai MP, Bleske BE, Zhang X, Lionberger R, Lee A, Amidon GL, Hasler WL, Sun D.

Mol Pharm. 2017 Dec 4;14(12):4295-4304. doi: 10.1021/acs.molpharmaceut.7b00425. Epub 2017 Oct 5.

PMID:
28937221
25.

Relationships of Vancomycin Pharmacokinetics to Body Size and Composition Using a Novel Pharmacomorphomic Approach Based on Medical Imaging.

Pai MP, Derstine BA, Lichty M, Ross BE, Sullivan JA, Su GL, Wang SC.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01402-17. doi: 10.1128/AAC.01402-17. Print 2017 Nov.

26.

Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.

Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Faragon C, Malik M, Mendes RE, Jones RN, McNutt LA, Lodise TP.

BMC Infect Dis. 2017 Aug 2;17(1):534. doi: 10.1186/s12879-017-2609-0.

27.

Valproic acid decreases brain lesion size and improves neurologic recovery in swine subjected to traumatic brain injury, hemorrhagic shock, and polytrauma.

Nikolian VC, Georgoff PE, Pai MP, Dennahy IS, Chtraklin K, Eidy H, Ghandour MH, Han Y, Srinivasan A, Li Y, Alam HB.

J Trauma Acute Care Surg. 2017 Dec;83(6):1066-1073. doi: 10.1097/TA.0000000000001612.

PMID:
28697014
28.

Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial.

Georgoff PE, Nikolian VC, Bonham T, Pai MP, Tafatia C, Halaweish I, To K, Watcharotone K, Parameswaran A, Luo R, Sun D, Alam HB.

Clin Pharmacokinet. 2018 Feb;57(2):209-219. doi: 10.1007/s40262-017-0553-1.

29.

Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study.

Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Lodise TP.

Diagn Microbiol Infect Dis. 2017 Jul;88(3):259-263. doi: 10.1016/j.diagmicrobio.2017.03.008. Epub 2017 Apr 2.

30.

Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations.

Pai AB, Meyer DE, Bales BC, Cotero VE, Pai MP, Zheng N, Jiang W.

Clin Transl Sci. 2017 May;10(3):194-200. doi: 10.1111/cts.12443. Epub 2017 Feb 3.

31.

Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers Bias.

Pai MP, Hong J, Krop L.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02490-16. doi: 10.1128/AAC.02490-16. Print 2017 Apr.

32.

Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis.

Rahbar AJ, Lodise TP, Abraham P, Lockwood A, Pai MP, Patka J, Rabinovich M, Curzio K, Chester K, Williams B, Morse B, Chaar M, Huang V, Salomone J.

Surg Infect (Larchmt). 2016 Dec;17(6):675-682. Epub 2016 Nov 14.

PMID:
27841954
33.

High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.

Auriti C, Falcone M, Ronchetti MP, Goffredo BM, Cairoli S, Crisafulli R, Piersigilli F, Corsetti T, Dotta A, Pai MP.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7333-7339. Print 2016 Dec.

34.
35.

Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults.

Pai MP.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4585-9. doi: 10.1128/AAC.00682-16. Print 2016 Aug.

36.

Optimizing the initial amikacin dosage in adults.

White BP, Lomaestro B, Pai MP.

Antimicrob Agents Chemother. 2015 Nov;59(11):7094-6. doi: 10.1128/AAC.01032-15. Epub 2015 Aug 17.

37.

Treatment of bacterial infections in obese adult patients: how to appropriately manage antimicrobial dosage.

Pai MP.

Curr Opin Pharmacol. 2015 Oct;24:12-7. doi: 10.1016/j.coph.2015.06.004. Epub 2015 Jun 25. Review.

PMID:
26119488
38.

Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment.

Hong J, Krop LC, Johns T, Pai MP.

Pharmacotherapy. 2015 May;35(5):455-63. doi: 10.1002/phar.1588.

PMID:
26011138
39.

Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects.

Justo JA, Mayer SM, Pai MP, Soriano MM, Danziger LH, Novak RM, Rodvold KA.

Antimicrob Agents Chemother. 2015 Jul;59(7):3956-65. doi: 10.1128/AAC.00498-15. Epub 2015 Apr 20.

41.

Do formulation differences between the reference listed drug and generic piperacillin-tazobactam impact reconstitution?

Zheng H, Truong J, Carroll F, Pai MP.

Antimicrob Agents Chemother. 2015 Mar;59(3):1767-9. doi: 10.1128/AAC.04563-14. Epub 2014 Dec 15.

43.

Innovative approaches to optimizing the delivery of vancomycin in individual patients.

Pai MP, Neely M, Rodvold KA, Lodise TP.

Adv Drug Deliv Rev. 2014 Nov 20;77:50-7. doi: 10.1016/j.addr.2014.05.016. Epub 2014 Jun 5. Review.

44.

Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin.

Zasowski E, Butterfield JM, McNutt LA, Cohen J, Cosler L, Pai MP, Gottwald J, Chen WZ, Lodise TP.

Antimicrob Agents Chemother. 2014 Jul;58(7):3804-13. doi: 10.1128/AAC.02632-13. Epub 2014 Apr 21.

45.

Reply to Di Paolo et al.

Falcone M, Russo A, Venditti M, Novelli A, Pai MP.

Clin Infect Dis. 2014 Jun;58(12):1789-90. doi: 10.1093/cid/ciu233. Epub 2014 Apr 11. No abstract available.

PMID:
24729497
46.

Epoetin in the 'untransfusable' anaemic patient: a retrospective case series and systematic analysis of literature case reports.

Heh-Foster AM, Naber M, Pai MP, Lesar TS.

Transfus Med. 2014 Aug;24(4):204-8. doi: 10.1111/tme.12120. Epub 2014 Apr 4. Review.

PMID:
24697987
47.

Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example.

Pai MP, Russo A, Novelli A, Venditti M, Falcone M.

Antimicrob Agents Chemother. 2014 Jun;58(6):3162-7. doi: 10.1128/AAC.02355-14. Epub 2014 Mar 24.

48.

Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity.

Pai MP, Rodvold KA.

Diagn Microbiol Infect Dis. 2014 Feb;78(2):178-87. doi: 10.1016/j.diagmicrobio.2013.10.011. Epub 2013 Oct 22. Review.

PMID:
24268292
49.

Polymyxin B dosing in obese and underweight adults.

Pai MP.

Clin Infect Dis. 2013 Dec;57(12):1785. doi: 10.1093/cid/cit604. Epub 2013 Sep 18. No abstract available.

PMID:
24051863
50.

Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.

Falcone M, Russo A, Venditti M, Novelli A, Pai MP.

Clin Infect Dis. 2013 Dec;57(11):1568-76. doi: 10.1093/cid/cit582. Epub 2013 Sep 17.

PMID:
24046298

Supplemental Content

Support Center